AstraZeneca stock holds near $157 after earnings beat
Published on 08/14/2026 at 07:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock is trading after a second-quarter update that showed diluted EPS of $2.63 on $15.38 billion in revenue, while shares were listed at $157.40 and the market cap stood at $244.02 billion as of August 14, 2026.
The latest quarter compared with $2.17 in EPS a year earlier, and revenue rose 6.4% year over year, even as the reported sales figure landed below the $15.44 billion expectation cited in market coverage.
Quarterly numbers
The move matters because the quarter combined a clear profit beat with modest top-line growth. On the same report, the consensus view in market coverage pointed to 10.21 earnings per share for the current year, which sets a high bar for the next updates.
That mix leaves valuation-sensitive investors focused on execution, not just headline growth. With a reported price of $157.40, a 1-year range of $145.79 to $212.71, and a 50-day moving average of $175.25, the stock is still trading below short-term trend levels.
What the market tracks
Trading data also showed a P/E ratio of 23.52 and a dividend yield of 1.98%, giving the shares a more mature profile than many large-cap healthcare names. The market cap of $244.02 billion is the bigger anchor for the story than any single-day swing.
For investors, the key comparison is simple: EPS of $2.63 versus $2.17 a year earlier, and revenue growth of 6.4% versus a consensus that expected $15.44 billion. That gap explains why the stock can hold attention even when the share price is well below its 52-week high of $212.71.
Drug portfolio
The company's oncology, rare disease, and cardiovascular portfolio remains the core of the business, with AstraZeneca quote data tracking the shares alongside those operating trends. For a company of this size, investors usually read every quarterly beat through the lens of pipeline durability and margin resilience.
Shares and valuation
AstraZeneca shares traded at $157.40 as of August 13, 2026, with market capitalization at $244.02 billion and a reported P/E ratio of 23.52. The shares were also below the 52-week high of $212.71 and above the 52-week low of $145.79.
Company details
Company: AstraZeneca plc
ISIN: US6549022043
Ticker: AZN
Exchange: Nasdaq
Price (as of August 13, 2026, 4:00 p.m. ET): $157.40 USD
Market cap: $244.02 billion (as of August 14, 2026)
Sector / Industry: Healthcare / Pharmaceuticals
Index membership: Nasdaq-100
